Anti-VEGF therapy (Ferrara & Adamis, 2016) or inhibitor of VEGFR2 trafficking (Yamada et al, 2017; Waters et al, 2021) is thus effective for cancer and blinding eye diseases. The gene discussed is VEGFA; the disease is eye disorder.